Cancer Banner

Dr. Paumi is working to determine the role of the multidrug resistance-associated proteins (MRP, ABCC) in metabolic quality control and cancer. Recent findings by Dr. Paumi suggest that casein kinase 2 (CK2) plays an important role in regulating MRP1 (ABCC1)-associated multidrug resistance (MDR) in cancer.  These studies have direct implications for the understanding of the role of the MRPs in cancer and toxin disposition, i.e., heavy metals such as Cd, As or Se.
Dr. Spear's research focuses on transcriptional regulation in the liver during development and disease and emphasizes the use of genetically-modified mouse models.  Historically, his research has focused on transcriptional repression during postnatal liver development and has used alpha-fetoprotein (AFP) as a model system.  AFP is an ideal gene for this purpose since it is expressed at high levels in the fetal liver, silenced at birth, and re-activated during liver regeneration and in liver cancer.  The Spear lab is working on the relationship between oxidative stress, liver cancer, and transcriptional control in collaboration with Dr. Howard Glauert.
Dr. Swanson's laboratory is focused on 1) understanding how exposures to environmental contaminants that act as aryl hydrocarbon receptor (AHR) agonists contribute to human diseases, in particular, cancer and 2) demonstrating that blocking the AHR can be an effective approach to be used for the treatment of relevant human disease states.
Dr. Orren's laboratory studies DNA damage, genomic instability and the cellular enzymatic pathways that minimize their deleterious effects on human health including cancer and other phenotypes associated with aging. One project investigates the WRN-and other RecQ helicase-dependent pathways that act in telomere maintenance and proper resolution of replication blockage.
Dr. Izumi's research is focused on DNA damage and mutagenesis, specifically those generated by reactive oxygen species (ROS).  Oxidative DNA damage is generated by internally produced ROS and exogenous DNA damaging reagents, such as ionizing radiation. DNA base excision repair (BER) is indispensable for normal cells to keep the genomic integrity intact against the continuous attack from ROS.  Apurinic/apyrimidinic endonuclease (APE1 in mammals) is a pivotal BER enzyme that also modulates the cellular redox state and regulates important transcription factors such as AP1, p53, and NF-kB via their reduction. Dr. Izumi’s lab currently focuses on how the activity of APE1 is regulated by post-translational modification including oxidation/reduction and ubiquitination.
Dr. Chen is investigating the mechanism for metal carcinogenesis, specifically arsenic-induced carcinogenesis and the role of autophagy.
Dr. St. Clair's research has been focused on investigating the fundamental mechanisms by which ROS and reactive nitrogen species (RNS) contribute to normal tissue injury and cancer formation in order to develop novel strategies for intervention.  These projects involve evaluating genetic abnormalities of antioxidant enzymes, the mechanisms regulating gene expression, and the impact these alterations have on the ability of humans to cope with oxidative stress generated from chemical carcinogens and environmental agents.
Dr. Yang's research is focused on cancer, specifically colon cancer.  Colorectal cancer is the second most fatal cancer in the US, largely due to invasion and metastasis to the liver and lymph nodes, and arises from somatic genetic changes that involve activation of oncogenes and/or inactivation of tumor suppressor genes. Dr. Yang is focused on the characterization of Programmed Cell Death 4 (Pdcd4), a novel tumor suppressor that is frequently down-regulated in several types of cancer.  In colon cancer tissues, expression of Pdcd4 is continuously down-regulated, i.e., normal>adenoma>carcinoma.  Over-expression of Pdcd4 inhibits tumor promoter-induced transformation and tumor phenotype in both cultured cells and mice.
Dr. Kyprianou research is focused on urologic oncology and prostate cancer, primarily on the genetic regulation of apoptotic and growth factor signaling pathways in prostate cancer.  Her laboratory has two main directions: (1) characterization of the impairment of the signaling network operated by the multifunctional cytokine, transforming growth factor-β (TGF-β), during prostate cancer progression, and 2) the resulting loss of apoptosis and cell cycle regulation in prostate cancer.  She uses proteomic approaches to study novel TGF-β signaling effectors in apoptosis in prostate cancer cells (in collaboration with Dr. Haining Zhu), and to investigate the mechanisms of androgen receptor signaling deregulation contributing to the development of hormone-refractory prostate cancer.
Dr. Gu's research focuses on mechanistic studies of DNA repair in human cancer and aging. One of her projects studies leukemogenesis and relapse. Her laboratory has recently demonstrated that both persistent (initially resistant to chemotherapy) and relapsed (acquired resistance) leukemias are closely associated with defects in DNA MMR.
Dr. Orazio's laboratory is focused on defining mechanisms by which UV radiation promotes mutagenesis and carcinogenic transformation of melanocytes, with a specific focus on the role of the melanocortin 1 receptor (MC1R), a transmembrane Gs-coupled receptor.
Dr. Luo is investigating in the cellular/molecular mechanisms underlying 1) ethanol-induced neuronal death, impaired cell cycle kinetics and disrupted cell migration in the developing brain and 2) how ethanol functions as a tumor promoter, particularly in the metastasis of breast cancer cells.
Dr. Vore's research is focused on the characterization of the function and regulation of expression of the organic anion transporters, particularly the ATP-Binding Cassette (ABC) efflux transporters that mediate the cellular efflux of glutathione and glucuronide conjugates of endo- and xenobiotics, and are thought to function in the elimination of end-products of metabolism.
Dr. Glauert is investigating the mechanism of carcinogenesis by environmental agents and the influence of nutrition.  Several diverse environmental chemicals, including phenobarbital, peroxisome proliferators, and PCBs, have tumor promoting activity in the liver.
Dr. Rangnekar's laboratory is investigating the molecular cross-talk between oncogenes and tumor suppressor genes in an effort to tilt the balance in favor of tumor suppressor gene expression or function. Dr. Rangnekar discovered the multi-faceted tumor suppressor protein Par-4 and has shown that its up-regulation induces apoptotic death specifically in cancer cells, while its absence leads to tumor growth and depression in mouse models.
Dr. Li's laboratory is focused on how DNA repair mechanisms play roles in preventing human diseases, including cancer, aging, and neurodegenerative disorders. A longstanding project in Dr. Li’s laboratory is DNA mismatch repair (MMR), a critical cellular mechanism that maintains genomic stability by both correcting mismatches generated during DNA metabolism (replication, combination, and repair) and mediating apoptosis of cells with severe DNA damage caused by physical and chemical reagents, including environmental carcinogens.
Dr. Wang's lab is focused on DNA damage-induced mutagenesis and its role in carcinogenesis.  Using various mouse tumor models, Dr. Wang’s lab examines if deleting the Rev1 gene in mice will indeed prevent various types of cancer such as lung cancer, skin cancer, pancreatic cancer, and liver cancer.
Dr. Wei is investigating how reactive oxygen species (ROS) contribute to carcinogenesis and cancer progression. The scope of the research includes the study of (1) intracellular signaling events mediated by ROS and environmental carcinogens, (2) unique molecular indicators of oxidative stress, and (3) understanding how these contribute to tumorigenesis, tumor promotion, and cancer progression. Current research is focused on elucidating the molecular mechanism by which Sulfiredoxin, a novel oxidative stress induced redox enzyme, promotes invasion and metastasis of human cancer cells.